U.N. virus therapy trial pauses hydroxychloroquine testing


Rafiq Maqbool – Associated Press

In this Tuesday, May 19, 2020 photo, a chemist holds a pack of hydroxychloroquine tablets in Mumbai, India. A Friday, May 22, 2029 report in the journal Lancet shows malaria drugs pushed by U.S. President Donald Trump as treatments for the coronavirus not only did not help but were tied to a greater risk of death and heart rhythm problems in a study of nearly 100,000 patients around the world.

GENEVA - The World Health Organization said Monday that it will temporarily drop hydroxychloroquine - the anti-malarial drug U.S. President Trump says he is taking - from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.

In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be "a temporary pause" on the hydroxychloroquine arm of its global clinical trial.



Reader Comments


Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2020